Selection of Macrolide Resistance

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(3):255-259

​ Stetsiouk O.U., Andreeva I.V.
Section
Correspondence
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(3):255-259
  • 1. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 2001; 29(5):251-6.
  • 2. Sefton AM. Macrolides and changes in the oral flora. Int J Antimicrob Agents 1999; 11 Suppl 1:S23-9.
  • 3. Cohen R. Approaches to reduce antibiotic resistance in the community. Pediatr Infect Dis J 2006; 25(10):977-80.
  • 4. Garcia-Rey C, Aguilar L, Baquero F, et al. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40:159-64.
  • 5. Karlowsky JA, Lagacé-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009; 34(4):375-9.
  • 6. Bell SC, Senini SL, McCormack JG. Macrolides in cystic fibrosis. Chron Respir Dis 2005; 2(2):85-98.
  • 7. Batt SL, Charalambous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2765-69.
  • 8. Gaynor BD, Chidambaram JD, Cevallos V, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol 2005; 89:1097-99.
  • 9. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356- 62.
  • 10. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebocontrolled study. Lancet 2007; 369(9560):482-90.
  • 11. Bingen E, Leclercq R, Fitoussi F, et al. Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002; 46(5):1199-203.
  • 12. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009; 15 Suppl 3:12-5.
  • 13. Hoban D, Baquero F, Reed V, Felmingham D. Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000. Int J Infect Dis 2005; 9(5):262-73.
  • 14. Reinert RR, Reinert S, van der Linden M, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005; 49(7):2903-13.
  • 15. Halpern MT, Schmier JK, Snyder LM, et al. Metaanalysis of bacterial resistance to macrolides. J Antimicrob Chemother 2005; 55(5):748-57.
  • 16. Kasahara K, Kita E, Maeda K, et al. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother 2005; 11(2):112-4.
  • 17. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect 2009; 15(8):1260-4.
  • 18. Siira L, Rantala M, Jalava J, et al. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob Agents Chemother 2009; 53(5):2066- 73.
  • 19. Sogstad MK, Littauer P, Aaberge IS, et al. Rapid spread in Norway of an erythromycin-resistant pneumococcal clone, despite low usage of macrolides. Microb Drug Resist 2007; 13(1):29-36.
  • 20. Cizman M. Experiences in prevention and control of antibiotic resistance in Slovenia. Euro Surveill 2008 Nov 13;13(46). pii:19038.
  • 21. Toltzis P, Dul M, Blumer J. Change in pneumococcal susceptibility to azithromycin during treatment for acute otitis media. Pediatr Infect Dis J 2007; 26(7):647-9.
  • 22. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337(7):441-6.
  • 23. De Rosa R, Avolio M, Stano P, et al. Disappearance of Streptococcus pyogenes macrolide resistance in an area of northeastern Italy: a possible link with rational longacting macrolide consumption. Infez Med 2009; 17(2):82- 7.
  • 24. Hsueh PR, Shyr JM, Wu JJ. Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan. Clin Microbiol Infect 2006; 12(3):296-8.
  • 25. Chen J, Liu L, Wang G, et al. Correlation between usage of macrolide antibiotic and resistance of Streptococcus pneumoniae clinic isolates from Chongqing children’s hospital. Pediatr Pulmonol 2009; 44(9):917-21.
  • 26. Mölstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 2008; 8(2):125-32.
  • 27. Van Eldere J, Mera RM, Miller LA, et al. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother 2007; 51(10):3491-7.
  • 28. Livermore DM, Reynolds R, Stephens P, et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 2006; 28(4):273-9.
  • 29. Фокин А.А., Рачина С.А., Козлов С.Н. Исследования использования лекарственных средств: методология проведения и перспективы практического применения в России. Клин фармакол и тер 2009; 18(1):86-92.
  • 30. Coenen S, Ferech M, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 2006; 58(2):418-22.
  • 31. Government of Canada. Canadian Provincial Consumption of Oral Macrolides in the community from 2000 to 2006, Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). Guelph, ON: Public Health Agency of Canada, 2007.
  • 32. Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАСI. Клин микробиол антимикроб химиотер 2005; 7(2):15466.
  • 33. Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pneumoniae в России в 19992005 гг.: результаты многоцентровых проспективных исследований ПеГАСI и ПеГАСII. Клин микробиол антимикроб химиотер 2006; 8(1):3347.
  • 34. Tyrrell GJ, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000- 2006. Vaccine 2009; 27(27):3553-60.
  • 35. Grivea IN, Tsantouli AG, Chryssanthopoulou DC, Syrogiannopoulos GA. Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2010; 29(1):97-105.
  • 36. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365(9462):855-63.
  • 37. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007; 26(2):123-8.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared